Anadrol,Buy Anadrol,Buy Steroids,Effects of Steroids
headerimage2
Home      |          Services      |     Resources      |     Site Map      |     Contact US
                  MENU
icon

Anadrol 50

icon Anadrol side effects
icon Buy anadrol
icon Anadrol for in
icon Anadrol cycle
icon Anadrol 50 oxymetholone
icon Anadrol 50 steroid
icon

Anadrol bold

icon Anadrol 75
icon Anadrol scion
icon Anadrol pill
icon Anadrol 50 side effects
   
  Featured Links
 
Anabolic Steroids
Buy Steroids
Buy Steroids
Steroid Abuse
   
Anadrol 50 oxymetholone :

Anadrol 50 oxymetholone is the U.S. brand name for oxymetholone, a very potent oral androgen. Since oxymetholone is quite reliable in its ability to increase red blood cell production, it showed great promise in treating cases of severe anemia. It turned out to be well suited for this purpose, and was popular for quite some time.  

Anadrol 50 oxymetholone drug is shown to have a much more direct effect on the red blood cell count, without the side effects of a strong androgen. Anadrol 50 is considered by many to be the most powerful steroid available, with results of this compound being extremely dramatic. A steroid novice experimenting with oxymetholone is likely to gain 20 to 30 pounds of massive bulk, and it can often be accomplished in less than 6 weeks, with only 50-100mg a day.  

Oxymetholone is a derivative of dihydrotestosterone, which gives it a structure that cannot be aromatized. As such, many have speculated as to what makes this hormone so troublesome in terms of estrogenic side effects. However we do find medical studies looking at this possibility. One such tested the progestational activity of various steroids including nandrolone, norethandrolone, methandrostenolone, testosterone and oxymetholone. 

Anadrol 50 oxymetholone is also a very potent androgen. This factor tends to produce many pronounced, unwanted androgenic side effects. Oily skin, acne and body/facial hair growth can be seen very quickly with this drug. Many individuals respond with severe acne, often requiring medication to keep it under control     

Anadrol 50 is the very strongest and at the same time, also the most effective oral steroid. The Anadrol 50 compound has an extremely high androgenic effect, which goes hand in hand with an extremely intense anabolic component. For this reason, dramatic gains in strength and muscle mass can be achieved in a very short time. An increase in body weight of 10 - 15 pounds or more in only 14 days is not un-usual.  

By the use of Anadrol 50, water retention is considerable, so that the muscle diameter quickly increases and the user gets a massive appearance within record time. Since the muscle cell draws a lot of water, the entire muscle system of most athletes looks smooth, in part even puffy. Anadrol does not cause a qualitative muscle gain but rather a quantitative one, which in the off-season is quite welcome. 

Anadrol "lubricates" the joints since water is stored there as well. On the one hand this is a factor in the enormous increase of strength and, on the other hand, it allows athletes with joint problems a painless workout. Power lifters in the higher weight classes are sold on Anadrol. A strict diet, together with the simultaneous intake of Nolvadex and Proviron, can significantly reduce water retention so that a distinct increase in the solid muscles is possible.  

By taking Anadrol the athlete experiences an enormous "pump effect" during the workout in the exercised muscles. The blood volume in the body is significantly elevated causing a higher blood supply to the muscles during workout. Anadrol increases the number of red blood cells, allowing the muscle to absorb more oxygen. The muscle thus has a higher endurance and performance level. 

The highly androgenic effect of Anadrol stimulates the regeneration of the body so that the often-feared "over-training" is unlikely. Anadrol helps more than any other steroid during dieting to maintain the muscle mass and to allow an intense workout. Many bodybuilders therefore use it up to about one week before a competition, solving the problem of water retention by taking anti-estrogens and diuretics so that they will appear bulky and hard when in the limelight.

Catalina Marketing Hires Johnson & Johnson Executive to Lead Health Care Services Division
ST. PETERSBURG, FL. March 9, 2010– Catalina Marketing Corporation, the global leader in precision marketing and shopper-driven media, today announced the appointment of Renee Selman as President of its health care division, Catalina...




GSK CEO Andrew Witty Dedicates albendazole Facility in Nashik to WHO?s Global Programme to Eliminate LF
LONDON, March 8, 2010--GlaxoSmithKline (GSK) CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole, part of a combination treatment used within the World Health...




Cardiff University and Merck Serono Launch International Survey For Couples Trying To Conceive
• Largest study aimed at understanding the fertility decision-making process of today’s couples trying to conceive • Survey available in twelve languages on www.startingfamilies.com Mumbai, India, March 9, 2010 – Merck Serono, a...




Exelixis Announces Restructuring
- Aligning Resources with Late-Stage Compounds XL184, XL147 and XL765 - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2010 - Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a consequence of its continued strategy to focus...




Nabi Closes License Deal With Glaxosmithkline
From Associated Press (March 8, 2010) ROCKVILLE, Md. -- Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. The deal is potentially worth more than $500 million,...




Mylan Rebukes and Cites Flaws in Bayer-Sponsored Mylan-Nifedipine Extended Release Bioequivalence Study in Canada
TORONTO, March 9 /CNW Telbec/ - Mylan (Nasdaq: MYL) today reported that it has identified multiple flaws within a purported bioequivalence study sponsored by Bayer Inc. of Canada. The study compared Bayer's antihypertensive Adalat(R) XL(R) tablets,...




Roche Suspends Arthritis Drug Study After Deaths
From Associated Press (March 8, 2010)   BASEL, Switzerland -- Swiss pharmaceutical company Roche Group said Monday it has suspended a late-stage trial for a new rheumatoid arthritis and lupus drug after several patients died from...




Roche and Biogen Idec Decide to Suspend Ocrelizumab Treatment - Rheumatoid Arthritis Development Programme on Hold
Future of the Ocrelizumab RA clinical programme under evaluation Basel, Switzerland, March 8, 2010--Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA)...




Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
CARLSBAD, Calif., March 8, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) related to the acceptance of...




XenoPort Restructures to Focus on Key Programs
SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar 5, 2010 - XenoPort, Inc. (Nasdaq:XNPT) announced today a restructuring that includes an overall reduction in its workforce of approximately 50%. The restructuring is designed to focus the Company's resources...




La Jolla Pharmaceutical Announces Termination of Merger Agreement with Adamis Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--Mar 5, 2010 - La Jolla Pharmaceutical Company (Pink Sheets: LJPC) today announced that La Jolla and Adamis Pharmaceuticals Corporation (OTCBB: ADMP) have agreed to terminate their merger agreement relating to the...




Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay Enterprises, Inc. (OTC:CHYE) (BULLETIN BOARD: CHYE) is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio...




Pfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9M
Pfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9M [The Day, New London, Conn.] From Day, The (New London, CT) (March 4, 2010) Mar. 4--As Pfizer Inc. continues a series of layoffs that are expected to total nearly 20,000 by the time its...




Pfizer, Bristol-Myers Say Clot Drug Meets Goals
From Associated Press (March 5, 2010) NEW YORK -- Bristol-Myers Squibb Co. and Pfizer Inc. on Thursday said their blood thinner apixaban was more effective than Sanofi-Aventis’ Lovenox in a late stage clinical trial. The study compared the...




Grassley Statement on GAO Report about FDA Office of Criminal Investigations
M E M O R A N D U M TO: Reporters and Editors RE: FDA Criminal Division DA: Thursday, March 4, 2010 Senator Chuck Grassley issued the comment below about a newly released report of the Government Accountability Office regarding the criminal division...




Abbott Executives To Chair Medical Device Lobby
From Associated Press (March 4, 2010) WASHINGTON -- The medical device industry’s chief advocacy group, AdvaMed, said Thursday an Abbott Laboratories executive will serve as its chairman. James Mazzo is President of Abbott Medical Optics, a...




Unilife and sanofi-aventis Agree to Exclusivity List for Unifill Ready-to-Fill Syringe
    LEWISBERRY, Pa., March 2 /PRNewswire-FirstCall/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ:UNIS) , today announced that it has agreed to a list of therapeutic drug classes ("Exclusivity List") within which sanofi-aventis...




Merck Statement on Vioxx Judgment in Australia
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Mar 5, 2010 - Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court...




District Court Upholds FDA's Grant of 5-Year Market Exclusivity to VYVANSE(R)
PHILADELPHIA, March 4, 2010/PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive...




H. Lundbeck A/S (DK) - Fourth Quarter and Full Year Report 2009 - Lundbeck Delivers 22 Percent Revenue Growth for 2009 and Meets Financial Expectations for 2009
COPENHAGEN, March 4, 2010--H. Lundbeck A/S (Lundbeck) announces 2009 results, which meet financial forecasts and continue to show growth in all regions. Full year revenue was DKK 13,747 million and increased 22% at constant exchange rates compared...




NICE Appraisal of azacitidine for Myelodysplastic Syndromes
LONDON, March 4, 2010--The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of azacitidine (Vidaza, Celgene) for myelodysplastic syndromes. In the final draft guidance, published today (4 March 2010), NICE...




Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment Community
Well-Positioned to Deliver in 2010 and On Track to Execute BioPharma Strategy Provides 2013 Minimum Non-GAAP EPS Guidance Will Present In-Depth Review of Robust, Differentiated Pipeline NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 - During a meeting...




KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs
    Judge Sentences St. Louis-Based Company to Pay $27.6 Million in Fines, Restitution and Forfeitures WASHINGTON, March 2 /PRNewswire-USNewswire/ -- Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV...




Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' Crinone Progesterone Gel Product Line
- Established, patient-preferred infertility treatment - - Expands Watson's Women's Health brand product portfolio - - Preterm birth clinical trials currently underway - - Company acquires 11.2 million shares of Columbia common stock - MORRISTOWN,...




Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Watson to acquire rights to CRINONE® and PROCHIEVE® and 11.2 million shares of common stock for upfront and milestone payments of up to $92.5 million plus royalties Also announces contingent agreements to retire debt Investor conference call...




Danish Lundbeck to Launch Two Depression Drugs in Phase III
From Nordic Business Report (March 3, 2010) 3 March 2010 - Danish pharma company H Lundbeck A/S (CPH: LUN) and its R&D partner Japanese TakedaPharmaceutical Company Ltd (TYO: 4502) said today they will start pivotal clinical phase III...




Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine
PRINCETON, N.J. & IRVINE, Calif.--(BUSINESS WIRE)--Mar 3, 2010 - Bristol-Myers Squibb Company (NYSE: BMY) and Allergan , Inc. (NYSE: AGN) today announced a global agreement for the development and commercialization of AGN-209323, a Phase...




Lundbeck and Takeda Finalize Plans to Initiate Phase III Pivotal Clinical Trials with Lu AA21004 and Lu AA24530
OSAKA, March 3, 2010--H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today jointly announced the plans for the additional clinical phase III studies on Lu AA21004 and phase III studies on Lu AA24530 in patients with...




Teva Announces Favorable Court Ruling in Generic Hyzaar and Cozaar Litigation
JERUSALEM--(BUSINESS WIRE)--Mar 2, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva's favor by overturning a July 31, 2009, district court...




FDA Grants Final Approval For Generic Flomax
From Associated Press (March 2, 2010) HAYWARD, Calif. -- Drugmaker Impax Laboratories Inc. said Tuesday the Food and Drug Administration gave final approval to its generic version of the enlarged prostate treatment Flomax. Impax plans to start...




Dendreon Rises; FDA Says No Meeting on Provenge
From Associated Press (March 2, 2010) WASHINGTON -- Shares of biotechnology company Dendreon Corp. jumped Tuesday after federal regulators said they don’t plan to hold a public meeting on the company’s prostate cancer treatment, possibly...




Nabi Shareholders Approve Deal With Glaxo
From Associated Press (March 2, 2010) ROCKVILLE, Md. -- Nabi Biopharmaceuticals said Tuesday shareholders approved its option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. More than 73 percent of Nabi’s...




Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as Chairman
NEW YORK--(BUSINESS WIRE)--Mar 2, 2010 - Bristol-Myers Squibb Company (NYSE:BMY) today announced that Lamberto Andreotti, 59, has been designated by the Board of Directors to serve as the company's chief executive officer, effective May 4, when...




Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced today the advancement of their...




Med Ad News' 21st Annual Manny Awards Will Honor Healthcare Advertising Agencies
MED AD NEWS' 21ST ANNUAL MANNY AWARDS WILL HONOR HEALTHCARE ADVERTISING AGENCIES NEWTOWN, Pa., March 2, 2010 - - On Thursday, April 22, 2010, Med Ad News magazine will host its 21st Annual Manny Awards celebrating creative excellence in...




Baxter to Acquire All Outstanding Equity of ApaTech, Including ACTIFUSE
DEERFIELD, Ill. and LONDON, U.K., March 1, 2010 – Baxter International Inc. (NYSE:BAX), a global, diversified healthcare company, and ApaTech, a private equity-backed, U.K.-based orthobiologic products company, today announced a...




Watson Signs Agreement to Divest Equity Interest in ScinoPharm
Intends to Use Proceeds to Support Business Development, General Business Purposes MORRISTOWN, N.J., March 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) today announced that it signed an agreement on February 26, 2010 to divest...




SuperGen Reports 2009 Fourth Quarter and Year-End Financial Results
Achieves net income for quarter & year of $2.3 million and $4.7 million, respectively Ends year with over $100 million in cash, cash equivalents & marketable securities DUBLIN, Calif.--(BUSINESS WIRE)--Mar 1, 2010 - SuperGen...




OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
- Advises Stockholders to Take No Action at this Time - MELVILLE, N.Y.--(BUSINESS WIRE)--Mar 1, 2010 - OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today confirmed that it has received an unsolicited proposal from Astellas Pharma Inc. ("Astellas") to...




Stull, Stull & Brody Announces Investigation on Behalf of Shareholders of OSI Pharmaceuticals, Inc.
NEW YORK--(BUSINESS WIRE)--Mar 1, 2010 - Attorney Advertising. Notice is hereby given that Stull, Stull & Brody has commenced an investigation on behalf of shareholders of OSI Pharmaceuticals, Inc. (“OSI” or the...




Home  |    Services   |   Resources   |   Site Map   |   Contact Us
Copy rights© reserved by ianadrol.com